Dendritic Cell Vaccine for Patients With Brain Tumors

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-08-21. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: tumorpatients mustbraincellsthe patient
  Phrases that lowered it: bodyvaccineclinical trialto evaluateevaluate the
• Sponsor's past termination rate: 3.4% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: 70 (lowers risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 3 (lowers risk) · Design
• Sponsor's past trials: 59 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 11 (raises risk) · Sponsor's track record
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports before start: 0 (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Disease area, dermatology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma NCT01635283 · started 2012 · scored riskier than 97% of active trials completed
• Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma NCT01792505 · started 2009 · scored riskier than 94% of active trials completed
• Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma NCT01808820 · started 2013 · scored riskier than 74% of active trials completed
• Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas NCT03334305 · started 2018 · scored riskier than 68% of active trials terminated
• Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Recurrence Of Glioblastoma Multiforme NCT04002804 · started 2010 · scored riskier than 32% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.